Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mianserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 8/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 7/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.97 |
| ▸ | HTR2B known ✓ | P41595 | 5/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 4/20 | 0.97 |
| ▸ | HTR1D known ✓ | P28221 | 3/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 3/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.97 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.97 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.97 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mianserin SCHEMBL29366576 | 1.00 | MEN1 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL29182002 | 0.99 | MEN1 (0.97) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL353397 | 0.98 | DRD3 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL29356897 | 0.98 | DRD3 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL9122085 | 0.98 | DRD3 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL23326358 | 0.98 | DRD3 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL18020 | 0.98 | DRD3 (1.00) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL11336834 | 0.97 | HTR2A (0.97) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL8344416 | 0.97 | DRD3 (0.97) | MEN1TP53CYP3A4KMT2AHPGD | |
| Mianserin SCHEMBL9752060 | 0.97 | DRD3 (0.97) | MEN1TP53CYP3A4KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1590 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | claimed |
| CN-119899192-A | Synthesis method of mianserin hydrochloride | 仁和堂药业有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-117777146-B | Mirabilin hydrochloride monohydrate crystal form I and preparation method thereof | 仁和堂药业有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119176757-A | Preparation method of mianserin hydrochloride intermediate and derivative thereof | 四川青木制药有限公司 | 2024-12-24 | — | — | CN | claimed |
| CN-118852173-A | Novel mianserin hydrochloride crystal form and preparation method thereof | 南京桦冠生物技术有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-117820319-A | Novel crystal form of mianserin hydrochloride and preparation method thereof | 仁和堂药业有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-117777144-A | Mirabilin hydrochloride novel crystal form II and preparation method thereof | 仁和堂药业有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117777146-A | Novel crystal form I of mianserin hydrochloride monohydrate and preparation method thereof | 仁和堂药业有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| US-11344496-B2 | Methods for preparing stabilized amorphous drug formulations using acoustic fusion | MERCK SHARP & DOHME CORP. (US) | 2022-05-31 | — | — | US | claimed |
| US-20050181049-A1 | Composition and method for enhancing bioavailability | ALZA CORPORATION | 2005-08-18 | — | — | US | claimed |
| WO-2005051358-A1 | COMPOSITION AND METHOD FOR ENHANCING BIOAVAILABILITY | ALZA CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| WO-2005004855-A1 | TREATMENT OF PREMATURE EJACULATION | WORLDWIDE PE PATENT HOLDCO PTY LTD (AU) | 2005-01-20 | — | — | WO | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004076675-A2 | GLUTAMATE TRANSPORT MODULATORY COMPOUNDS AND METHODS | JOHNS HOPKINS UNIVERSITY (US) | 2004-09-10 | — | — | WO | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20040063612-A1 | Neuroprotective agents | CARBOMER, INC. | 2004-04-01 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0651638-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT FOR SEROTONIN DEPLETION ILLNESS | IVY, Mary Elisabeth (ZA) | 1995-05-10 | — | — | EP | claimed |
| WO-1994002138-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT FOR SEROTONIN DEPLETION ILLNESS | IVY, MARY, ELIZABETH (ZA) | 1994-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | DRD3 4375/4885HTR2A 2503/4885DRD2 4671/4885 |
| US-11344496-B2 | Methods for preparing stabilized amorphous drug formulations using acoustic fusion | PDE8B, RPS27A, PDE8A | DRD3 3802/4885HTR2A 4310/4885DRD2 4027/4885 |
| US-20040063612-A1 | Neuroprotective agents | GAP43, NLN, NOS3 | DRD3 2809/4885HTR2A 1077/4885DRD2 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.